Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,880 | 0,975 | 13:56 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.04. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT (1) UNUSUAL PRICE MOVEMENT; AND (2) SHARE PURCHASE BY TRUSTEE PURSUANT TO SHARE AWARD SCHEME | 1 | HKEx | ||
27.03. | BIOCYTOGEN-B (02315): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023 | 2 | HKEx | ||
25.03. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Kooperation mit ABL Bio, um neue bispezifische Antikörper-Wirkstoff-Konjugate zu entwickeln | 191 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), ein weltweit tätiges Biotechnologieunternehmen, das sich auf die Entwicklung neuartiger Antikörpertherapeutika konzentriert... ► Artikel lesen | |
25.03. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates | 149 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies... ► Artikel lesen | |
15.03. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 1 | HKEx | ||
23.02. | BIOCYTOGEN-B (02315): ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE YEAR ENDED DECEMBER 31, 2023 | 1 | HKEx | ||
20.02. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen und Gilead schließen ein Abkommen über die Zusammenarbeit bei Multi-Target-Antikörpern | 552 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) gibt heute den Abschluss einer Vereinbarung mit Gilead Sciences, Inc. über die Evaluierung von Antikörpern und die Gewährung... ► Artikel lesen | |
20.02. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement | 357 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access... ► Artikel lesen | |
19.02. | Gilead signs antibody deal with Biocytogen amid ADC buzz | 8 | Pharmaceutical Technology | ||
19.02. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BIOCYTOGEN AND GILEAD ENTER INTO A MULTI-TARGET ANTIBODY COLLABORATION AGREEMENT | 2 | HKEx | ||
23.01. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen führt RenBiologics ein, eine Untermarke, die sich auf die Auslizenzierung vollständig menschlicher Antikörper für die therapeutische Entwicklung konzentriert | 320 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) gab heute die Einführung einer neuen Untermarke, RenBiologics, bekannt, die für den Geschäftsbereich Antikörperforschung... ► Artikel lesen | |
09.01. | Biocytogen and Radiance partner for bispecific antibody-drug conjugate | 2 | Pharmaceutical Technology | ||
08.01. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Vereinbarung über bispezifische Antikörper-Wirkstoffkonjugate mit Radiance Biopharma | 337 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), ein weltweit tätiges Biotechnologieunternehmen, das sich auf die Entwicklung neuartiger Antikörpertherapeutika konzentriert... ► Artikel lesen | |
08.01. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BIOCYTOGEN ENTERED INTO A BISPECIFIC ANTIBODY DRUG CONJUGATE AGREEMENT WITH RADIANCE BIOPHARMA | 1 | HKEx | ||
20.12.23 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Multi-Target-Vereinbarung in Bezug auf Antikörper mit Neurocrine Biosciences ab | 394 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) gab heute den Abschluss einer Vereinbarung über die Evaluierung von Antikörpern und eine entsprechende Option mit Neurocrine... ► Artikel lesen | |
20.12.23 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BIOCYTOGEN ENTERED INTO MULTI-TARGET ANTIBODY AGREEMENT WITH NEUROCRINE BIOSCIENCES | 2 | HKEx | ||
18.12.23 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors | 324 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibody... ► Artikel lesen | |
18.12.23 | Biocytogen and Ona enter cancer ADC development deal | 2 | Pharmaceutical Technology | ||
18.12.23 | Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors | 287 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibody... ► Artikel lesen | |
18.12.23 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BIOCYTOGEN ENTERS INTO ANTIBODY AGREEMENT WITH ONA THERAPEUTICS TO DEVELOP ANTIBODY-DRUG CONJUGATES TARGETING ... | 2 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MEDIGENE | 1,710 | -10,47 % | Medigene startet Kapitalerhöhung zu 1,20 Euro je neuer Aktie | Das Biotech-Unternehmen Medigene startet eine Kapitalerhöhung: Gegen Bezugsrecht sollen bis zu rund 4,912 Millionen neue Medigene Aktien emittiert werden, womit die Zahl ausgegebener Anteilscheine auf... ► Artikel lesen | |
BIOFRONTERA | 0,346 | 0,00 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Kapitalerhöhung aus Genehmigtem Kapital | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Kapitalerhöhung aus Genehmigtem Kapital
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Leverkusen (pta/04.04.2024/19:45)... ► Artikel lesen | |
CLINUVEL | 8,980 | +2,92 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL expands global leadership team | ||
EDITAS MEDICINE | 5,378 | +2,01 % | Editas Medicine, Inc.: Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting | ||
BLUEBIRD BIO | 0,908 | +1,32 % | bluebird bio, Inc. - 8-K, Current Report | ||
ASEP MEDICAL | 0,110 | +4,76 % | Asep Medical bestätigt, dass der Einsatz von KI verbesserte Behandlungen der häufigen Biofilminfektionen und eine schnelle Sepsisdiagnose ermöglicht | VANCOUVER, BC, 13. März 2024 - In seiner jüngsten Präsentation vor der US-amerikanischen Biophysical Society in Philadelphia1 berichtete Dr. Bob Hancock, CEO von Asep Medical Holdings... ► Artikel lesen | |
BELLEROPHON THERAPEUTICS | 0,001 | -100,00 % | Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology; Athersys, Inc.; Borqs Technologies; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition; Evelo Biosciences ... | NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of SmileDirectClub, Inc. SmileDirectClub, Inc.'s securities were suspended on... ► Artikel lesen | |
CARDIFF ONCOLOGY | 4,045 | -0,98 % | Cardiff Oncology, Inc.: Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study | RAS-mutated mCRC - In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 2,980 | -0,67 % | Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update | FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization... ► Artikel lesen | |
FRESH TRACKS THERAPEUTICS | 0,730 | 0,00 % | Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th | Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks... ► Artikel lesen | |
CLEAN HARBORS | 183,60 | 0,00 % | Should You Invest in Clean Harbors (CLH)? | ||
MESOBLAST | 0,535 | +10,54 % | If you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now! | ||
CSTONE PHARMACEUTICALS | 0,102 | 0,00 % | CSTONE PHARMA-B (02616): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023 | ||
SPERO THERAPEUTICS | 1,350 | +2,27 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update | On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Initiated enrollment in PIVOT-PO... ► Artikel lesen | |
PROTALIX BIOTHERAPEUTICS | 1,066 | -3,40 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results | Company to host conference call and webcast today at 8:30 a.m. EDT
CARMIEL, Israel, March 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company... ► Artikel lesen |